Post-Traumatic Stress Disorder – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of pharmacological agents. Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are often used in the first line. Given the multiple symptom domains that affect PTSD patients, combination therapy with anxiolytics and benzodiazepines, as well as mood stabilizers, is common. Atypical antipsychotics may be prescribed to patients who do not respond to earlier lines of therapy. Given patients’ variable comorbid symptoms, treatment of PTSD is highly individualized. In this report, we use national patient-level claims data to explore the use of key therapies for PTSD in both newly diagnosed and recently treated patients.
QUESTIONS ANSWERED
- What shares do key therapies and brands garner by line of therapy in newly diagnosed PTSD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PTSD patients?
- How have atypical antipsychotics been integrated into the treatment algorithm, and what is their source of business?
- To what extent is Lundbeck/Otsuka’s Rexulti—in late-phase development for PTSD—already used in PTSD patients?
- What percentage of PTSD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PTSD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Allergan, Janssen, Lundbeck, Otsuka, Sunovion, Takeda
Key drugs: SSRIs, SNRIs, anxiolytics, Rexulti, aripiprazole, Vraylar, Trintellix, bupropion
Key analysis provided:
- Brand/therapy use across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more-detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Table of contents
Matthew D. Litke, M.S., Lead Healthcare Research & Data Analyst, CNS and Ophthalmology. Mr. Litke supports Clarivate’s Treatment Algorithms Claims Data Analysis report series, in addition to authoring syndicated content in the CNS and ophthalmology therapy areas. He holds a B.S. in biochemistry and molecular biology from Penn State University and an M.S. in psychology from Villanova University.